{"publication_id":"df81d398-48f0-4b72-9ba2-3a198be21ae8","screening":{"identified":54,"screened":54,"excluded":0,"included":54,"included_or_retained":54,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"54 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["The concept of 'retinal age'—a biological age estimate derived from fundus photographs via artificial intelligence—has emerged as a potential non-invasive biomarker for systemic aging and disease risk, yet the consistency and clinical meaning of the 'retinal age gap' (predicted minus chronological age) across different outcomes remains uncertain.","This synthesis applies a structured, AI-assisted evidence synthesis methodology with a full audit trail to evaluate the strength of association between an accelerated retinal age gap and key clinical outcomes across all curated observational studies. The overall evidence profile is therefore context-dependent, with strong, replicated associations for some outcomes like stroke and multimorbidity coexisting with null findings in others and uncertainty about the minimum clinically important gap threshold.","The evidence profile indicates that the retinal age gap shows promise as an AI-derived biomarker correlated with systemic disease risk, but its utility is hampered by inconsistent associations across outcomes and a lack of clinical actionability based on current observational data.","The curated corpus is composed exclusively of observational cohort studies, systematic reviews, and preclinical animal models; no randomized controlled trials of retinal-age-gap-guided intervention appear in the reference set. This absence means that the causal arrow from an accelerated retinal age gap to downstream clinical action — screening escalation, treatment initiation, or preventive counseling — remains untested within this evidence base. The limitation is therefore not one of association strength but of intervention proof: the synthesis cannot address whether retinal-age-gap biomarkers meet the bar for clinical decision-making that would require prospective, randomized validation.","For retinal age ai, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support Retinal Age AI as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 54 curated reference papers, the evidence base for Retinal age AI shows a context-dependent profile. Negative signals appear in: immune inflammation, contextual other. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Retinal age AI anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}